Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FACT - K Release!
Guess that takes the fear out of the Q10.
Go Leo & IPIX!
https://mailchi.mp/ipharminc/innovation-pharmaceuticals-concludes-successful-phase-2a-trial-of-kevetrin-for-ovarian-cancer-intra-tumor-modulation-of-p53-observed?e=3a6ad1bd8e
That's the way I read it. K is worth $$$$$$.
Go Leo & IPIX!
Just checking in. So Menon took a pay cut. Awesome and confident.
They are cutting cost of continuing the phase 2 OC trial because they proved the moa. Now see money is only in Oral? So they said Oral is worth moving forward? They will jump to phase 2 Oral.
I will read the Q tonight.
Deal is done.
Bunny, IMO I only see good things in IPIX's future. P news will be soon.
Go Leo & IPIX!
More FACTS! Thanks slcimmuno, B OM could be our first deal!
2018 = Nasdaq
Go Leo & IPIX!
OM - Magnitude of Unmet Need
Future OncologyVol. 13, No. 30 Special Report (December 2017)
US oncology-wide incidence, duration, costs and deaths from chemoradiation mucositis and antimucositis therapy benefits
Abstract only, full article behind paywall... reads as it'd be chock-full of OM data. Googled author, CEO of ProThelial... a Device for OM, so not playing in same ballpark as B-OM, other drugs in development... still some data on magnitude of OM need - costs, mortality -- again, liking our chances -- 60% or higher -- for BTD given FT given to every company going after OM and not nec showing prevention (like us, Galera -- two leaders, with our Oral Rinse the much better mode of delivery... and likely less expensive - per the bulk commercial-grade manufacturing legwork IPIX PR'd)
----
Approximate oncology-wide incidence, duration, costs and deaths associated with mucositis and identify health economic benefits of antimucositis therapies. Review the literature relevant to the clinical experience of mucositis by pathophysiology, incidence, duration, costs and deaths. Use US insurance actuarial and epidemiology on cancer to generalize an oncology-wide impact of toxic mucositis. Toxic mucositis causes oropharyngoesophageal ulcerations, chemo-induced nausea, vomiting and diarrhea. Acutely, it lasts 102 days/six cycles of chemotherapy, 60 days in human stem-cell transplantation patients and 70–84 days in head and neck cancer patients at annual costs of US$13.23 billion/522,166 treated patients (US$20,892/erosive-type mucositis patient, US$25,337/physiologic mucositis patient) and 46,699 deaths. Using antimucositis therapies prior to 2013 provided fractional benefits at high costs. By completely preventing and rapidly reversing mucositis, high-potency polymerized cross-linked sucralfate promises superior health economic benefits.
https://www.futuremedicine.com/doi/abs/10.2217/fon-2017-0418
https://www.accessdata.fda.gov/cdrh_docs/pdf12/K123904.pdf
I love FACTS George. Please send us more.
Go Leo & IPIX!
Trust the FACTS and here are the FACTS
Innovation has developed three lead drug candidates—each with first-in-class potential across multiple clinical indications attributable to novel mechanisms of action—with dermatology, oncology, anti-inflammatory and antibiotic applications.
Prurisol—an orally-delivered medicine for treating psoriasis
Kevetrin—a non-genotoxic anti-cancer drug that modulates p53
Brilacidin—an immunomodulatory agent with anti-inflammatory/antibiotic properties
Based on sound science, and covered by strong intellectual property and patent protections, these drug candidates are in mid-to-late stage clinical trials.
Advancing under a number of special FDA designations to help expedite development, improve likelihood of drug approval and gain market exclusivity, they address large areas of unmet medical need and represent sizable commercial opportunities.
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5a4e5519c8302529ed8ed663/1515083038575/2018Jan+IPIX+Corporate+Overview.pdf
Good luck and GOD bless,
George
Soon mich, good post! Any day we could receive the big news that will change everything.
Go Leo & IPIX!
IPIX is much further advanced compared to when it was 4 dollars a share..
I would say DE RISKED not risk free <wink>
I would also guess we didn't have 20 CDAs back then either <wink>
Also.. there was a time when we had only a couple CDAs.. then there were 5..then 10..then...
I wonder if the first few who signed on are getting impatient?.
Lol.. saying things like.. "it's just around the corner..its just around the corner!!" <wink>
Contraire;).. this has been a process that has been building and building (value that is)..
All part of the plan..
The "next" corner is one we have NEVER seen before.
GOOD LUCK TO ALL REAL IPIX SHAREHOLDERS
Thanks, that was awesome. Whoever said money can't buy you happiness...
Go Leo & IPIX!
Love the bunny rabbit cartoons in your post... Rabbit stew, mmmmm...
Go Leo & IPIX!
Pete, you hit some very good points. Thanks,
Go Leo & IPIX!
I see no reason to worry if the stock moves up or down less than a penny. Til news, all movement, especially on small volume, meaningless IMO. That is why I expect the rest of Feb to be fairly quiet.
News on K-OC trial or pill advancement, B news on Compassionate/Extended Use or other FDA approved means to get to users quicker, plans for dermatology and topical cream delivery system, etc will just set the table for the big Prurisol top line news.
The Prurisol top line news should make the financial world finally aware of how devastating IPIX's pipeline is and how undervalued it is. Should make a nice pop and only fools would then trade it while awaiting the hammer to drop on the first deal. That may come right after P announcement, a few weeks later, or possibly a month or two later but since nobody knows when the trading should be quite light until it does. If I was Leo, I would plan a PR for K pill advancement just a day or two prior to P top line results so market sees that all 3 drugs are going to be huge!
The first deal blows the lid off of share price and from there the sky is the limit.
Of course, if some BP gets real itchy (and smart) to bottle up the pipeline early for some outrageous amount, then that wraps up the game right there.
Bunny, what do you mean by "way over their skis on this one"
Go Leo & IPIX!
IMO, You are asking for us to choose one of your three options so here is my choice. Please use the second option; using passenger pigeons will make this board much more constructive and allow us to focus on the facts instead of FUD.
Thank you!
Go Leo & IPIX!
I would say we are doing pretty good today considering the market condition over the past week.
Go Leo & IPIX!
IMO, I have never met the IPIX team but I am sure their work is not about money and is more about helping/curing people. Passionate people can do amazing things and I think that is what IPIX is going to do. There is no doubt in anyone's mind who follows this board who the shorters are and who the longs are.
Time is going to tell us who is on the right/winning side. I don't like to lose.
2018 = Nasdaq
Go Leo & IPIX!
he wouldn't die broke either making 400,000 salary. But yet he can make 250 million+ on his 28 million shares.
The shorts argument is utterly ridiculous.
I would agree; they seem to be working overtime, on the weekends and evenings.
2018 = Nasdaq
Go Leo & IPIX!
Take that, you wascally wabbit! Good to have you back Karin...
Go Leo & IPIX!
I found the following post of interest since there are some clear differences pointed out between the stock in your example and this biotech company. You may want to review it closely to see how the preferred shares actually impacted your example company.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138239514
Quote:
"The latest one I've watched up close is ACRL which has gone from 50 cents a share to 1/10 of a cent per share using this method in seven months on extraordinary volumes." by 'Suvorov'
Others may not "contest your example of the abuse of preferred shares" but I sure do.
ACRL was a hot mess long before their preferred shares were authorized. They had issued hundreds of thousands of dollars worth of convertible notes (NOT to insiders) at steep discounts to the market and the price had already collapsed when the Preferred was proposed by the Board.
Specifically the share price dropped from 52 cents (on negligible volume, btw) to a penny between March and August of 2017.
The SCHEDULE 14C INFORMATION STATEMENT advising the public of the Board resolution to create the Preferred wasn't filed until September 20th.
As of the latest company filing the Preferred hadn't been issued.
Great example.
I suggest you go back and follow the dilution of this company over the years. You may want to start out when you see the company was a step from bankruptcy years ago when current management chose to lend the company money instead of entering a detrimental finance contract.
Management has since been moving the science forward over the years on minimal dilution and without the common reverse split that most early stage biotech do. The company is finally in a spot where it will likely find a partner or buyer for one of its drugs or the entire company. Those preferred shares aren't a concern to me.
Objectivity may be important, but, only with a full understanding of the company one is talking about.
In Reply to 'Suvorov'
You are incorrect, I didn't infer I was an expert in biotech ,I am an expert in financial balance sheets and the tricks derived, thereby, from financial structures used to the detriment of the common shareholder's interest.
A balance sheet of a bio tech company, a mining company or a company planning to go to the moon all share the same characteristics on a balance sheet.
There isn't a difference.
IPIX could have the best drugs ever in the market 2 to 5 years from now; however, if between now and then financial tricks have been played because of cash crunches or just general greediness , like 'preferred shares death spiral' the common shareholders now might get enormously diluted, cheated by management or a 'black knight.'
I suggest you guys get familiar with a balance sheet and don't get too misty eyed or 'fall in love' with your stock. Any stock. That emotion subverts anyone's reason, sense. Always be objective, like I am.
Hope that clears up your misunderstanding of my expertise.
In my opinion.
Great reminder! thanks sox.
Go Leo & IPIX!
Reasons why IPIX is very busy.
1. ~20 CDAs
2. B-dermatitis formulation / partnership negotiation
3. B-OM clinical study report / BTD application
4. B-OM sachets
5. B-UP oral / gel formulation
6. K oral formulation
7. K-OC trial
8. P trial
Nice!
Go Leo & IPIX!
Karin,
I am very sorry for your loss. Cancer is a horrible disease. May she rest in peace.
Good questions George. I can only surmise that they know how much money IPIX will be worth soon. When they finally decide to let go and jump in the share price is going to climb fast. You could think it was a vendetta but this is purely money motivated.
I can barely wait for next 60 days to see where we will be.
2018 = Nasdaq
Go Leo & IPIX!
IPIX closed unchanged after being up for the majority of the day.
There were a lot of people working hard all day trying to stop the momentum and reverse the climb in share price.
Who are these people that work so hard all day to attempt to drive the price of IPIX down???
Why are these people expending so much time and effort to drive the price of IPIX down???
Good luck and GOD bless,
George
Awesome post petemantx!
Go Leo & IPIX!
I am in complete agreement with you. We are most likely within 60 days of getting the Prurisol and Kevetrin results and hearing of a deal(s). Those are the only things that matter at this point in time. We already know IPIX has a multi-billion property in Brilacidin, all that remains is finding out if we add both Prurisol and Kevetrin to that list and I would say most would say the odds like pretty good.
All the talk about daily trading and the price moving pennies up and down is just so much BS. How many plan on trading out of their position within the next 60 days? Nobody but the traders and since that is their thing I would hope we wouldn't have to listen about it daily. The MM's hold all the cards between now and the BIG news, IPIX has no control over them, what they can do is superfluous to our long term success, so it is insane to worry about their games.
Investors are always looking for the golden ring. IMO we have found it in IPIX. Those that talk it down are dolts IMO so I pay them no heed, those that they influence are fools for whom I feel no pity, and those that want to chance playing the trading game for pennies I say go for it but quit your whining when you play it wrong. I don't care to hear about it.
As for me, I will have a great Feb regardless of what the stock price does because I know we have finally reached the jackpot at the end of the rainbow and no talk about the sky falling is going to change my opinion.
As in the movies (I liked Lord of the Rings) it is now about time for the "Return of the Kings" and to me that is Krishna and Leo.
A reasonable person can read yesterdays release and conclude that this stock will not be held down for much longer. The company that does so much with so little.
We have some more news coming hopefully this week.
Go Leo & IPIX!
January 29, 2018
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
Brilacidin
BEVERLY, MA – January 29, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update:
· The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;
· A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;
· After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.
Brilacidin—Dermatology Formulation Development
Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.
To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.
For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:
· “Brilacidin’s Potential Application in Dermatology”
For more on Brilacidin, learn more here:
· http://www.ipharminc.com/brilacidin-1/
IMO those "mistakes" are learning lessons. As long as he learns from these situations and it certainly appears he has I will continue to trust and believe in Leo. I have tried my entire life to focus on the "present" and not the past because the past cannot be changed. I think CTIX/IPIX has been dealing with cyber-terrorism for a couple of years now and that is our new reality.
There are a lot of amazing things happening at IPIX and I propose that when the right news is released the mass will overcome this terrorism and the people & IPIX will prevail. We are dealing with peoples lives not just money.
Go Leo & IPIX
I’ve not always been a fan of Leo’s, he’s made many significant mistakes and in summation has allowed the FUD spreaders to own the narrative. That all changes once he gets a deal. Financially and moving the products forward he’s done a fantastic job but he certainly isn’t wining over the hearts and minds of Wall Street. Lucky for us Art has the technical skills necessary to get the ball over the goal line. T-90 days...
© 2018 InvestorsHub.com, Inc.
Leo Ehrlich and Krishna Menon are obviously doing amazing work with IPIX. 20 CDA's for their pipeline. That is no joke.
Go Leo and IPIX!
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
BEVERLY, Mass., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update:
The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;
A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;
After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.
Brilacidin—Dermatology Formulation Development
Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.
To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.
For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:
“Brilacidin’s Potential Application in Dermatology”
For more on Brilacidin, learn more here:
http://www.ipharminc.com/brilacidin-1/
Question: does your interpretation vary depending whether it is on the big board or OTC?
Thanks Tom.
Go Leo & IPIX
If the good news cake is baked ...
and ready to run, we might see a surge right to 95 and 1.05 area and then weathering the pullback, maybe at 85 area,to solidify support zone in the 80's, then take off from there. could set the stage for a bigger rally to start looking at those targets around the 200ma. 1.50-1.75 etc. maybe even 2 dollars .
chart view
this has been the target picture for many weeks ,while it waited around 65/70 cents.
a more complete Fib target picture here
a surge to 1.06 has a 50% fib retrace target back at 86, and the 50 ma should act as a support line when the time comes. any real bounce happening now, upon real good news, should start reality moving forward now.
Fibonacci targets around 1.70/1.80/2.00
....at the same time, today's rally bounce, looks like it got Capped for the final 1 hour 40 minutes. so its still being kept under some 'control', maybe?
76 cap
septmike09, a very short but powerful post. We are getting close.
Go Leo & IPIX!
Now that was funny! I can laugh because my mother is from Italy.
Go Leo & IPIX!
BAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHA...
GIOVANNI ....GO MAKA US SOM PASTA FOR DA CELEBRATION COMING SOON !
GO IPIX !
You could be right. I was making my presumption from the release title/heading which was for Brilacidin. Either way we are looking pretty good. There is a ton of interest in this company and we are looking pretty solid right now. Can't wait to see how 2018 plays out.
Go Leo & IPIX!
I don’t think that’s just B! I think it’s a total number for all drugs. Jmo
I would have been satisfied with 5-10
But approaching 20 really proves the interest IPIX has and can show how dedicated they are to pleasing as they have trial designs and anchoring to please the possible partners.
I’m feeling Kevetrin may surprise us soon. People here have no idea just how valuable K could be.
© 2018 InvestorsHub.com, Inc.
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
BEVERLY, Mass., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update:
The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;
A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;
After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.
Brilacidin—Dermatology Formulation Development
Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.
To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.
For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:
“Brilacidin’s Potential Application in Dermatology”
For more on Brilacidin, learn more here:
http://www.ipharminc.com/brilacidin-1/
I still can't believe there are 20 CDA's for JUST B. Leo has positioned this company for success. It's going to happen soon!
Go Leo & IPIX!
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
BEVERLY, Mass., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update:
The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;
A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;
After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.
Brilacidin—Dermatology Formulation Development
Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.
To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.
For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:
“Brilacidin’s Potential Application in Dermatology”
For more on Brilacidin, learn more here:
http://www.ipharminc.com/brilacidin-1/
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
This is awesome news! 20 CDA's Holy cow that is some serious interest in B!
Go Leo & IPIX!
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
BEVERLY, Mass., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update:
The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;
A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;
After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.
Brilacidin—Dermatology Formulation Development
Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.
To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.
For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:
“Brilacidin’s Potential Application in Dermatology”
For more on Brilacidin, learn more here:
http://www.ipharminc.com/brilacidin-1/
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
Leo is the bomb! He keeps pounding out progress and that's all I can ask for. OTC offering up a chance of a life time - IPIX's shares at bargain basement prices. This is going to be a life changer...
2018 = Nasdaq
Go Leo & IPIX!
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
BEVERLY, Mass., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides a business development update:
The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;
A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;
After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.
Brilacidin—Dermatology Formulation Development
Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.
To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.
For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:
“Brilacidin’s Potential Application in Dermatology”
For more on Brilacidin, learn more here:
http://www.ipharminc.com/brilacidin-1/
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
Sox, you also must be rated an EXPERT poster. Thank you for some more factual posting and some citations I can reference for myself.
Go Leo & IPIX!
Recent IBD Deals
1. Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug (preclinical)
"Johnson & Johnson has landed rights to Protagonist Therapeutics’ preclinical Crohn’s disease asset PTG-200. The deal gives J&J a stake in an oral interleukin-23 (IL-23) receptor antagonist in return for $50 million upfront and up to $940 million in milestones."
"The asset is due to enter the clinic this year. Protagonist will run and fund the trial with J&J taking over—and covering 80% of the costs—once it advances to phase 2. Beyond this, a series of major paydays await Protagonist. J&J will pay Protagonist $125 million if it moves the drug into phase 2b and a further $200 million if it sticks with the asset after getting a look at data from the trial. The rest of the cash is tied to regulatory and sales milestones."
http://www.fiercebiotech.com/biotech/j-j-commits-990m-to-land-protagonist-s-oral-crohn-s-drug
2. Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases
"Celgene Corporation (CELG) today announced it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of approximately $7.2 billion, net of cash acquired."
http://www.fiercepharma.com/pharma/celgene-completes-acquisition-of-receptos-advancing-leadership-immune-inflammatory-diseases
3. Celgene enters deal potentially worth over $2.5 billion for Nogra Pharma's Crohn's disease drug
"Celgene announced a global licensing deal Thursday potentially valued at more than $2.5 billion to develop and market Nogra Pharma's experimental drug GED-0301 for moderate-to-severe Crohn's disease and other indications."
https://www.firstwordpharma.com/node/1205296?tsid=1
4. Gilead swoops down on Galapagos JAK1 candidate filgotinib in $2.075B deal
"Gilead Sciences Inc., is stepping in where Abbvie Inc. stepped out, laying down a whopping $725 million, with up to $1.35 billion more to come in milestones, for rights to Galapagos NV's Janus kinase 1 (JAK1)-selective inhibitor filgotinib (GLPG0634)."
http://www.bioworld.com/content/gilead-swoops-down-galapagos-jak1-candidate-filgotinib-2075b-deal
5. Salix Expands in GI Drugs and Beyond with $2.6B Santarus Acquisition
"Salix Pharmaceuticals said it will acquire Santarus for about $2.6 billion, in an all-cash deal that expands the buyer’s gastrointestinal (GI) drug portfolio and extends its product offerings into primary care and diabetes."
http://www.genengnews.com/gen-news-highlights/salix-expands-in-gi-drugs-and-beyond-with-2-6b-santarus-acquisition/81249089
George, you must be rated as an EXPERT poster? The difference between a "pro" vs. "EXPERT" rated poster is that an "EXPERT" rated poster references source of information with a citation listed within the body of their posts like you do. The "pro" rated posters only give one sentence with little to know substance.
Thank you for posting factual information on this board and being an "EXPERT" poster!
Not long now...
Go Leo and IPIX!
Otezla (Apremilast) is derivative of thalidomide. Younger people should look up thalidomide.
https://en.wikipedia.org/wiki/Development_of_analogs_of_thalidomide
Apremilast:
Development of apremilast[edit]
Figure 4: Molecular structure of apremilast, an analog of thalidomide
After finding a novel set of analogs of thalidomide, namely 3-(1,3-dioxo-1,3 dihydroisoindol-2-yl)-3-(3,4-dimethoxyphenyl) propionic acid (not shown), which had PDE4 inhibition activity the work began to optimize the activity. For that purpose the researchers used a known structure moiety, 3,4-dialkoxyphenyl, that is a recognized pharmacophore in PDE4 inhibitors such as rolipram (Figure 6) and roflumilast and added it onto the structure of the previously mentioned analog series. After tweaking the structure and testing different substitution at the 4-position of the phthaloyl ring and at the carboxyl acid the researchers finally landed at a molecule that potently inhibits PDE4 and TNF-a, which they later named apremilast (Figure 4). The S-enantiomer of apremilast was chosen since it was the more active enantiomer.[21] Since the structure of apremilast lacks the acidic chiral hydrogen it should not racemize in vivo, unlike thalidomide, lenalidomide and pomalidomide.[42][43]
Structure-activity relationship[edit]
Figure 5: Thalidomide with the ring system outlined
Since the mechanism of action of thalidomide and its analogs is not fully clear and the bioreceptor for these substances has not been identified, the insight into the relationship between the structure and activity of thalidomide and its analogs are mostly derived from molecular modelling and continued research investigation.[43][44] The information on SAR of thalidomide and its analogs is still in process so any trends detailed here are observed during individual studies. Research has mainly focused on improving the TNF-a and PDE4 inhibition of thalidomide,[7][21] as well as the anti-angiogenesis activity.[45][46]
TNF-a inhibitors (not via PDE4)[edit]
Research indicated that a substitution at the phthaloyl ring would increase TNF-a inhibition activity (Figure 5). An amino group substitution was tested at various locations on the phthaloyl ring (C4, C5, C6, C7) of thalidomide and EM-12 (previously described). Amino addition at the C4 location on both thalidomide and EM-12 resulted in much more potent inhibition of TNF-a. This also revealed that the amino group needed to be directly opposite the carbonyl group on the isoindolinone ring system for the most potent activity.[47] These analogs do not inhibit PDE4 and therefore do not act by PDE4 inhibition. Other additions of longer and bigger groups at the C4 and C5 position of the phthaloyl ring system of thalidomide, some with an olefin functionality, have been tested with various results. Increased inhibitory effect, compared to thalidomide, was noticed with the groups that had an oxygen atom attached directly to the C5 or C4 olefin. Iodine and bromine addition at C4 or C5 resulted in equal or decreased activity compared to thalidomide.[48] These groups were not compared with lenalidomide or pomalidomide.
PDE4 inhibitors[edit]
Figure 6: Rolipram, highlighting the 3,4-dialkoxyphenyl moiety
Figure 7: Common structure for PDE4-inhibiting thalidomide analogs
The common structure for analogs that inhibit TNF-a via inhibition of PDE4 is prepared on the basis of hydrolysing the glutarimide ring of thalidomide. These analogs do not have an acidic chiral hydrogen, unlike thalidomide, and would therefore be expected to be chirally stable.[42]
On the phenyl ring, a 3,4-dialkoxyphenyl moiety (Figure 6) is a known pharmacophore in PDE4 inhibitors such as rolipram. Optimal activity is achieved with a methoxy group at the 4-position (X2) and a bigger group, such as cyclopentoxy at the 3-position carbon (X3). However the thalidomide PDE4 inhibitory analogs do not follow the SAR of rolipram analogs directly. For thalidomide analogs, an ethoxy group at X3 and a methoxy group at X2, with X1 being just a hydrogen, gave the highest PDE4 and TNF-a inhibition.[21] Substitutes larger than diethoxy at the X2–X3 position had decreased activity. The effects of these substitutions seem to be mediated by steric effects.[42]
For the Y-position, a number of groups have been explored. Substituted amides that were larger than methylamide (CONHCH3) decrease PDE4 inhibition activity.[42] Using a carboxylic acid as a starting point, an amide group has similar PDE4 inhibition activity but both groups were shown to be a considerably less potent than a methyl ester group, which had about six-fold increase in PDE4 inhibitory activity. Sulfone group had similar PDE4 inhibition as the methyl ester group. The best PDE4 inhibition was observed when a nitrile group was attached, which has 32 times more PDE4 inhibitory activity than the carboxyl acid.[21] Substituents at Y leading to increasing PDE4 inhibitory activity thus followed the order:
COOH ≤ CONH2 ≤ COOCH3 ≤ SO2CH3 < CN
Substitutions on the phthaloyl ring have been explored and it was noticed that nitro groups at the C4 or C5 location decreased activity but C4 or C5 amino substitution increased it dramatically.[42] When the substitution at the 4 (Z) location on the phthaloyl ring was examined, hydroxyl and methoxy groups seem to make the analog a less potent PDE4 inhibitor. An increase in activity was observed with amino and dimethylamino to a similar extent but a methyl group improved the activity further than the aforementioned groups. A 4-N-acetylamino group had slightly lower PDE4 inhibitory activity, compared with the methyl group, but increased the compound's TNF-a inhibitory activity to a further extent.[21] Substituents at Z leading to increasing PDE4 inhibitory activity thus followed the order:
N(CH3)2 ≤ NH2 < NHC(O)CH3 < CH3
Thalidomide:
https://en.wikipedia.org/wiki/Thalidomide
Good luck and GOD bless,
George
Thank you once again George for posting the facts.
Quote:
With a 20% drug price discount applied to all biologics, the annual health plan costs for brodalumab, adalimumab, ustekinumab, secukinumab, ixekizumab, and etanercept were estimated at $37,224, $49,166, $55,084, $56,061, $64,396, and $57,170, respectively.
https://www.ncbi.nlm.nih.gov/pubmed/29357713
The annual health plan costs for brodalumab (SILIQ™) $37,224
The annual health plan costs for adalimumab (Humira) $49,166
The annual health plan costs for ustekinumab (STELARA®) $55,084
The annual health plan costs for secukinumab (Cosentyx) $56,061
The annual health plan costs for ixekizumab (Taltz) $64,396
The annual health plan costs for etanercept (Enbrel) $57,170
The annual health plan costs for apremilast (Otezla) $31,992
Based on:
Quote:
The average wholesale price for a 30-day supply (60 tablets) of apremi-last 30 mg is $2,666
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517531/
Good luck and GOD bless,
George
Bunny uses the word "sled" a lot, what a coincidence. The share price will go up with the pipeline IPIX has!
Go Leo & IPIX!
How about the PR, Dana Farber said to get that Kevetrin report ready for publication, will you bet all your shares on that?
Mako could have a field day with Leo, let's face it, that's why the sled is where it is today.
Thanks DaubersUP,
These last few posts are getting me so pumped its not funny!
2018 = Nasdaq
Go Leo & IPIX!
’m a bull and think this. Truly.
The only people that know about this stock are on iHub. There is a mass team of posters that want this lower. I do not know who or what entity they are. But they exist and you can see that by the day after day posts. Some are dual and more identities posting positive at some points and then turn to screw with retail Mom an pop investors like me to screw with our emotions. I know of one poster and 3 of their identities using a vpn to hide network configuration.
Anyways...with that said I believe there is a major goal to take this company lower.
Now, everyone here probably has that negative gulp and nervous feeling about IPIX. Because of the well coordinated day after day “play”
If you take yourself out of this board and never read it. For example my friend who is a brilliant investor and plays a penny here and there in bio based on science and mgmt etc... he has not one once of nervousness.
He just accumulated 100k worth of shares or is in the midst of finishing his position and Prurisol is his love. After speaking with him...I almost come back to earth/reality and feel great......and then I read this board.
We are extremely undervalued imo. Ask mgmt what they think of you ever speak to them. They feel the recent BOM results alone should have this at multiples of current share price. They are biased obviously and they do know 98% more than any of us....but they also KNOW what BP thinks... so when they think it should be multiples then that’s where we should be NOW.
Throw in a partnership for the B franchise I would expect major upfront cash MAJOR MAJOR milestones for multiple indications and major royalties. Based on future estimates in these indications and market share we ideally are looking at a humira type drug.
As the drug continues to pan out I do believe 20 dollars is an easy target. That is after uplist and major institutional support.
Amen Brother!
Great post.
Go Leo & IPIX!
untoHIM
Correction there were no, NOT ONE, severe patients in the Phase 2a Prurisol trial but 67% were classified as moderate IGA 3 and 33% were classified as mild IGA 2 at baseline prior to starting treatment.
The Prurisol Ohase 2b had only subjects classified as moderate or severe at baseline prior to starting treatment.
I predict approximately 82.5% of subjects taking Prurisol in the Phase 2b trial will have achieved PASI75 within just 84 days of treatment.
Good luck and GOD bless,
George
Thank you for the reminder!
Go Leo & IPIX!
It's taking time but rest assured that Leo is on the hunt.
My Fellow Shareholder,
I want to take a moment this morning to share with you an interesting article recently published by The Wall Street Journal. I encourage everyone to read John R. Emshwiller’s article, titled, “One Man’s Bid to Clear His Name Online: 4 Years, $3 Million and Some Dead Turtles.” The article struck a chord with me, as it lends some color to how certain characters leverage anonymity on the Internet to smear the good name of others only in an attempt to benefit themselves.
In his article, Mr. Emshwiller succinctly tells the story of real estate investor Bradley Cohen’s fight to expose the individuals behind an online assault on his business and character, make his name righteous again and bring the offenders to justice. Cohen must deal with fake news, relentless adversaries hiding behind the Frist Amendment, nefarious websites hosted in foreign countries and more.
Ultimately, Cohen’s perseverance paid off and he was successful on all counts, leading to a historic legal case and $38 million judgment in his favor.
I share this with all of you because it exemplifies that dark side of the Internet and the lengths that some bad actors will go to. It also proves that with persistent effort and the right resources that those individuals can be identified, no matter how cleverly they believe they have covered their tracks.
We assured you that the lawsuit by the Rosen Law Firm was frivolous. The court agreed. We didn’t stop there. You can believe me that our team is on top of bringing the culprits behind the attack on Cellceutix to justice.
We encourage current and future CTIX shareholders to rely only upon credible sources, including our news releases, research data and filings with the Securities and Exchange Commission. To that point, I am pleased to say that as of this morning we are still on target to provide an efficacy report this week from the second cohort in the open label Phase 2 trial of Brilacidin for ulcerative colitis. We also are looking forward in the coming weeks to releasing an interim analysis of data from the double-blind Phase 2 study of Brilacidin-OM for the prevention and treatment of oral mucositis.
These are truly exciting times at Cellceutix and I thank you for the ongoing support.
All the best,
Leo
2/27/17
Glad I don't have any of the 1,121,200 short shares. Hopefully the squeeze will start this week!
Go Leo & IPIX!
Over a million shares of IPIX are currently shorted
That is not insignificant.
INNOVATION PHARMACEUTICALS INC
Short Interest (Shares Short)
1,121,200
Short Interest Ratio (Days To Cover)
2.3
http://shortsqueeze.com/?symbol=ipix&submit=Short+Quote%E2%84%A2
GOD bless,
George
All that work but I guess the pay off will be not having to invest until it rockets off to $50+. There is definitely a cycle that keeps repeating itself and should be investigated but it really won't matter soon.
Go Leo & IPIX!
Amazing. All the MM and Shorts hard work all day and they only got it down $.0007? I got to say though - they are persistent.
Wish all the Longs a Very nice weekend.
For factual information please see the IPIX website. Always do your due diligence when trading stocks. It is not recommended to trade on the advise of a poster.
http://www.ipharminc.com/
Go Leo & IPIX!